8-K/A: Cytokinetics Aficamten Data Shows Cardiac Improvement

Cytokinetics presented new data on aficamten at the European Society of Cardiology Congress 2025, highlighting improved cardiac structure and function and a low incidence of atrial fibrillation.

Summary

• Additional data for aficamten was presented at the European Society of Cardiology Congress 2025, including analyses from MAPLE-HCM and FOREST-HCM studies.
• A pre-specified analysis from MAPLE-HCM showed aficamten was superior to metoprolol in improving measures of diastolic function and reducing mitral valve systolic anterior motion (SAM) and mitral valve leaflet-septal contact (all p<0.001).
• Aficamten treatment led to a significant decrease in maximal wall thickness by -1.01 mm (95% CI -1.8 to -0.2, p=0.015) compared to metoprolol, though left ventricular mass index (LVMI) reduction was not significantly different.
• A new analysis from FOREST-HCM indicated an annual incidence rate of new-onset atrial fibrillation (AF) with aficamten of 1.5% among patients without a history of AF, consistent with expected rates in validated prediction models.
• Long-term treatment with aficamten in FOREST-HCM demonstrated early and sustained hemodynamic and clinical benefits over a mean follow-up of 62 weeks and maximum of 170 weeks, with a low incidence of new-onset AF and LVEF <50%.
• At Week 12 and Week 96, 69% and 93% of patients, respectively, reported a 1 New York Heart Association (NYHA) Functional Class improvement from baseline.
• Patients experienced a mean increase in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) of 15 and 16 points at Week 12 and Week 96, respectively (p<0.0001).
• An integrated safety analysis across three clinical trials (REDWOOD-HCM, SEQUOIA-HCM, MAPLE-HCM) and FOREST-HCM, involving 463 participants and almost 700 patient-years of exposure, showed aficamten was well-tolerated with an adverse event profile similar to placebo.
• Aficamten is currently under regulatory review by the U.S. FDA with a PDUFA target action date of December 26, 2025, and also by the European Medicines Agency (EMA) and China National Medical Products Administration (NMPA).

Sentiment

Score: 9

Explanation: The filing presents highly positive clinical data for aficamten, demonstrating superiority over standard-of-care, significant improvements in cardiac function and symptoms, and a favorable safety profile. This significantly de-risks the asset and enhances its commercial potential, indicating strong progress towards regulatory approval.

Positives

• Aficamten demonstrated superiority over metoprolol, the current standard-of-care, in improving measures of diastolic function and reducing LVOT obstruction contributors.
• Significant decrease in maximal wall thickness observed in aficamten-treated patients compared to metoprolol.
• The annual incidence rate of new-onset atrial fibrillation (1.5%) with aficamten is consistent with expected rates in patients with HCM and healthy individuals, suggesting no increased risk.
• Long-term treatment with aficamten showed sustained hemodynamic and clinical benefits, including significant reductions in LVOT-G and improvements in NYHA Functional Class and KCCQ-CSS.
• The integrated safety analysis confirmed aficamten is well-tolerated with a low incidence of LVEF <50% and new-onset AF, comparable to placebo and metoprolol.
• No permanent discontinuations related to aficamten treatment were observed in the integrated safety analysis.

Negatives

• The reduction in left ventricular mass index (LVMI) was not significantly different when comparing aficamten to metoprolol.
• One patient (1.1%) treated with aficamten experienced transient LVEF <50% without heart failure or treatment interruption in MAPLE-HCM.
• One patient (0.3%) in FOREST-HCM terminated treatment due to ischemic colitis, which was determined not to be related to aficamten.

Risks

• Potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression, product sale, manufacturing, or production of drug candidates.
• Drug candidates may have adverse side effects or inadequate therapeutic efficacy.
• The FDA or foreign regulatory agencies may delay or limit the ability to conduct clinical trials.
• Inability to obtain or maintain patent or trade secret protection for intellectual property.
• Standards of care may change, rendering drug candidates obsolete.
• Competitive products or alternative therapies may be developed by others for the treatment of targeted indications.

Future Outlook

Aficamten is an investigational drug candidate currently under regulatory review in the U.S. by the FDA, with a PDUFA target action date of December 26, 2025. It is also under review by the European Medicines Agency (EMA) and the China National Medical Products Administration (NMPA) with Priority Review. The company continues to evaluate aficamten in ACACIA-HCM (Phase 3, non-obstructive HCM), CEDAR-HCM (pediatric oHCM), and FOREST-HCM (open-label extension).

Management Comments

• "The echocardiographic results from MAPLE-HCM elaborate on the superiority of aficamten compared to the current standard-of-care metoprolol as was previously reported in the primary efficacy analyses." Fady I. Malik, M.D., Ph.D., Cytokinetics Executive Vice President of Research & Development.
• "The additional data presented at the ESC Congress 2025 continue to strengthen the evidence base supporting the overall safety profile of aficamten, including as has been observed with a real-world dosing strategy." Fady I. Malik, M.D., Ph.D., Cytokinetics Executive Vice President of Research & Development.

Industry Context

Hypertrophic cardiomyopathy (HCM) is the most common monogenic inherited cardiovascular disorder, affecting an estimated 280,000 diagnosed patients and 400,000-800,000 undiagnosed patients in the U.S. Aficamten, a selective cardiac myosin inhibitor, targets the myocardial hypercontractility associated with HCM, aiming to improve exercise capacity and relieve symptoms. The positive clinical data for aficamten positions it as a potentially significant new therapeutic option in a market with substantial unmet need, particularly for patients with obstructive HCM.

Comparison to Industry Standards

• Aficamten demonstrated superiority over metoprolol, a current standard-of-care for HCM, in improving diastolic function and reducing LVOT obstruction.
• The observed annual incidence rate of new-onset atrial fibrillation (1.5%) with aficamten is consistent with expected rates from validated prediction models in patients with HCM (HCM-AF: 3.6% per year) and healthy individuals (CHARGE-AF: 1.4% per year), suggesting a favorable safety profile regarding AF risk compared to natural disease progression and general population rates.

Stakeholder Impact

• Shareholders: Positive impact due to strong clinical data, de-risking of a key pipeline asset, and progress towards regulatory approvals, potentially increasing future revenue and market value.
• Patients with HCM: Highly positive impact as aficamten demonstrates superior efficacy over current standard-of-care and a favorable safety profile, offering a new, potentially more effective treatment option.
• Healthcare Providers: Positive impact by providing a new therapeutic tool that shows significant improvements in cardiac function and symptoms for HCM patients.
• Regulatory Authorities: The detailed clinical data supports the ongoing review processes for aficamten in multiple jurisdictions.

Next Steps

• Continued regulatory review of the New Drug Application (NDA) for aficamten by the U.S. FDA, with a PDUFA target action date of December 26, 2025.
• Ongoing regulatory review of Marketing Authorization Application (MAA) for aficamten by the European Medicines Agency (EMA).
• Ongoing regulatory review of NDA for aficamten by The Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) with Priority Review.
• Cytokinetics will host an investor webcast on September 2, 2025, to discuss the primary results from MAPLE-HCM and other data.
• Continued evaluation of aficamten in ACACIA-HCM (Phase 3, non-obstructive HCM) and CEDAR-HCM (pediatric oHCM) clinical trials.

Key Dates

Recommendation

The filing presents compelling positive clinical data for aficamten, demonstrating superiority over standard-of-care metoprolol, significant improvements in cardiac function and symptoms, and a favorable safety profile with low incidence of key adverse events like atrial fibrillation and LVEF reduction. With regulatory reviews underway and a PDUFA date set, these strong results significantly de-risk the asset and enhance its commercial potential, making it a strong buy for investors. The data suggests a high likelihood of regulatory approval and successful market entry, positioning Cytokinetics for substantial growth.

Keywords

Aficamten, Hypertrophic Cardiomyopathy, HCM, Cardiac Myosin Inhibitor, Cytokinetics, MAPLE-HCM, FOREST-HCM, European Society of Cardiology Congress, Atrial Fibrillation, FDA, NDA, PDUFA, Clinical Trial, Cardiovascular